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Cognitive function in young people with and without perinatal HIV in the AALPHI cohort in 
England: the role of non-HIV related factors 
 
ABSTRACT 
 
Background: There is limited evidence about the cognitive performance of older adolescents with 
perinatally-acquired HIV (PHIV+) compared to HIV-negative (HIV-) adolescents. 
Methods: 296 PHIV+ aged 12-21 and 97 HIV- aged 13-23 completed 12 tests covering 6 cognitive 
domains.  HIV- adolescents were siblings of PHIV+ and/or had an HIV positive mother.  Domain-
specific and overall (NPZ-6) z-scores were calculated for PHIV+ with and without CDC class C 
disease and HIV-.  Linear regression explored predictors of NPZ-6. 
Results: 125(42%) PHIV+ and 31(32%) HIV- were male, 251(85%) and 69(71%) were black African, 
and median age was 16[IQR 15,18] and 16[14,18] years respectively. In PHIV+, 247(86%) were on 
ART, and 76(26%) had a previous CDC C diagnosis. Mean NPZ-6 scores were -0.81 (standard 
deviation 0.99) in PHIV+ with a CDC C diagnosis, -0.45 (0.80) in PHIV+ without CDC C, and -0.32 
(0.76) in HIV- (p<0.001).  After adjustment, there was no difference in NPZ-6 between PHIV+ 
without a CDC C and HIV- participants (adjusted coefficient -0.01 (95%CI -0.22, 0.20) for PHIV+ no 
C versus HIV-).  PHIV+ with CDC C scored below the HIV- group (adjusted coefficient -0.44 (-0.70, -
0.19)).  Older age predicted higher NPZ-6 score, whilst black African ethnicity and worse 
depression predicted lower NPZ-6.  In a sensitivity analysis including PHIV+ only, no HIV-related 
factors apart from CDC C were associated with NPZ-6. 
Conclusions: Cognitive performance was similar among PHIV+ without CDC C diagnoses and HIV-, 
and indicated relatively mild impairment compared to normative data. The true impact on day-to-
day functioning needs further investigation. 
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Cognitive function in young people with and without perinatal HIV in the AALPHI cohort in 
England: the role of non-HIV related factors 
 
INTRODUCTION 
Previous research has described global and specific cognitive impairments in perinatally HIV-
infected children in the era of combined antiretroviral therapy (cART).[1-3]  This group typically 
does not perform as well as controls on general cognitive tasks, processing speed and visual-
spatial tasks, and may have higher risk for behavioural problems and psychiatric disorders.[1, 4-7]  
Markers of HIV disease severity, including high viral replication,[5, 8] low CD4 cell counts,[7] and 
having a CDC C diagnosis,[3, 5, 9, 10] have been associated with poorer cognitive function.[2]  In 
addition, encephalopathy (itself an AIDS-defining symptom) is associated with a rapidly 
progressive early disease and residual serious neurologic consequences.[11] Although the 
incidence of encephalopathy has declined with increased cART availability,[12] many children do 
not start ART in early life and are at risk of longer-term cognitive effects of HIV. 
Knowledge about the cognitive performance of perinatally HIV-infected young people (PHIV+) is 
limited as most studies have small sample sizes and/or have recruited younger children or those 
just entering adolescence.[8, 13, 14]  Some findings suggest similar cognitive impairment in PHIV+ 
to perinatally HIV exposed uninfected (PHEU) youth, but poorer scores in both groups compared 
to normative data,[3] highlighting the importance of having appropriate control groups for 
comparison, for two reasons.  Firstly, non-HIV related factors may be contributing to lower 
cognitive performance in both PHIV+ and PHEU groups compared to normative data.  In many 
settings, families affected by parental HIV are likely to have different environmental and 
psychosocial experiences and socioeconomic status to families not exposed to HIV, and these 
factors may influence cognitive performance.[15]  For example, in the USA, many children with 
HIV (and PHEU siblings) are affected by poverty, trauma and parental drug use.[16]  In the 
UK/Irish perinatal HIV cohort, a high proportion of PHIV+ are born abroad in sub-Saharan Africa, 
and so have key differences compared to the wider population of adolescents born to families 
residing permanently in the UK.[17]  Secondly, many cognitive tests are validated on specific 
groups and so manufacturer normative data may not be applicable to young people,[18, 19] for 
whom critical changes in maturation take place during adolescence which may affect cognitive 
outcomes.[20, 21] 
This study explored the association between HIV, psychosocial, environmental, lifestyle and 
mental health factors on cognition in a large cohort of older PHIV+, as well as a comparable 
control group of adolescents affected by HIV, in England.  We asked a broader range of questions 
than have previously been studied, including psychosocial and environmental factors.  We 
hypothesised that these broader factors, as well as CDC disease stage may be associated with 
cognitive performance. 
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METHODS 
The Adolescents and Adults Living with Perinatal HIV (AALPHI) cohort is a prospective study 
evaluating the impact of HIV infection and ART exposure on perinatally HIV-infected and 
(predominantly sibling) HIV negative young people.  Participants were approached in 18 HIV 
clinics and 4 community services in England between 2013-2015, and underwent a two hour face–
to--face interview with a trained research nurse.  PHIV+ were aged 13-21 years and were all 
included in the national UK and Ireland Collaborative HIV Paediatric Study (CHIPS), with perinatal 
HIV confirmed through the National Study of HIV in Pregnancy and Childhood.[17, 22, 23]  HIV 
negative (HIV-) young people were: aged 13-23 years; HIV negative on a point-of-care test at 
interview; lived in the same household as a PHIV+ participant in AALPHI, or had a sibling, friend or 
partner who was a PHIV+ in AALPHI, or had an HIV-infected parent (non-mutually exclusive 
categories); and awareness of HIV in the family (where appropriate).  All participants had lived in 
the UK for ≥6 months, and could speak and understand English.  Full ethical approval was 
obtained from Leicester Research Ethics Committee. 
The cognitive assessment measured 12 tests across six domains (Supplementary Table 1), giving a 
comprehensive overview of the domains found to be affected in HIV-infected adults and children.  
Interviewers completed full training and had ongoing supervision (from D. Melvin, chartered 
Clinical Psychologist) to maintain standards and minimise intra-interviewer variability. 
Seven tests were administered via the computerised CogStateTM battery (Melbourne, 
Australia),[24, 25] validated in HIV-infected adult patients, and largely non-language based.[26]  
Participants completed one full practice test prior to each task to obtain optimal performance at 
baseline.[27]  Five tests were paper-based, including Color Trails 1 and 2 for speed of information 
processing and executive function respectively, WAIS-IV coding/ digit symbol for attention and 
working memory,[28] and Grooved Pegboard for dominant/non-dominant hand fine motor 
skills.[29]  The Hospital Anxiety and Depression Scale (HADS) was chosen as a measure of anxiety 
and depression as it has been used widely in the UK, was self-report and easy to complete. 
ART was defined as receipt of ≥3 ART drugs from ≥2 classes.  The Centers for Disease Control and 
Prevention (CDC) clinical classification system[30] was used to indicate class B moderately 
symptomatic infection and class C past history of an AIDS-defining illness. 
Statistical analysis 
Data were analysed using STATA version 13 (Stata Corp, College Station, Texas, USA).  Scoring of 
CogStateTM tests followed manufacturer recommendations.  For each test, z-scores were 
calculated using manufacturer normative data, adjusted for age where appropriate 
(Supplementary Table 1), and then averaged to give mean z-scores for each domain compared to 
the reference mean.  Normative data were not available for WAIS IV and so only the CogStateTM 
Identification Task contributed to the attention/working memory domain.  Summary NPZ-6 score 
was calculated as the mean z-score across all domains.  Cognitive impairment was defined as the 
proportion of participants with a z-score <-1 in ≥2 domains.[19, 31] 
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Mean z-scores were compared using t-tests and ANOVA, proportions using χ2 test, and medians 
using Wilcoxon rank sum.  The effect of potential predictors on NPZ-6 score was explored using 
linear regression and Wald p-values.  Factors considered a priori to be associated with NPZ-6 for 
all participants were HIV status and CDC disease stage (HIV-, PHIV+ CDC N/A/B, PHIV+ CDC C), sex, 
age, ethnicity, and being born outside of the UK.  Other variables considered were: psychosocial 
(death of one/both parents, currently living with parents, occupation, having a parent or carer in 
work; ever excluded from school); environmental (fostered/adopted; number of main carers 
(different adults taking responsibility for and living with the participant during childhood); main 
language spoken at home (English only v other); residential deprivation score (Income Deprivation 
Affecting Children Index (IDACI), ranging from 0-1; higher score = more severe deprivation)); 
lifestyle (tobacco, alcohol, drugs); and mental health (HADS,[32] ranging from 0-21; higher scores 
indicate more severe anxiety or depression)). 
A sensitivity analysis excluding PHIV+ with CDC C encephalopathy explored whether any 
differences by CDC C stage were sustained for other CDC C diagnoses, and another sensitivity 
analysis allowed for clustering by sibling pairs.  An additional analysis included HIV-related 
indicators for PHIV+ young people only (with pre-AALPHI data collected through the CHIPS 
cohort): year first presented to treatment, age diagnosed with HIV, age starting ART, current ART 
status, current efavirenz (EFV) use, nadir and most recent CD4 cell count, most recent viral load, 
median cumulative years with viral load<400 copies/ml, CDC stage, ever diagnosed with 
encephalopathy.  Variables attaining a p value of less than 0.15 in univariable analyses were 
considered in multivariable analysis using backwards selection.  Additionally characteristics of 
PHIV+ in AALPHI were compared to perinatally HIV-infected young people aged 13-21 years not in 
AALPHI but in the national UK/Ireland CHIPS cohort by 31 October 2013.[17, 22]  
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RESULTS 
A total of 296 PHIV+ participants and 97 HIV- completed cognitive testing.  Of the 97 HIV- 
participants: 50 (52%) had an HIV-infected mother; 37 (38%) were siblings of PHIV+ in the study; 6 
(6%) had PHIV+ siblings who were not in the study; and 4 (4%) had a close friend who was a PHIV+ 
(non-mutually exclusive categories).  Sociodemographic characteristics of PHIV+ and HIV- young 
people were similar (Table 1).  There were more females than males in each group, the median 
age for both groups was 16 years, most were black African and born outside of the UK, and most 
attended school and lived with their parents at the time of interview. Around a quarter (24%) of 
HIV- participants had experienced the death of one or both parents, compared to 36% of PHIV+, 
and median age at first parent death was 6 years (IQR 2, 10) and 7 years (4, 10) respectively.  
Similar proportions reported having ever smoked and used alcohol, and mean anxiety and 
depression HADS scores were similar.  The median age at which PHIV+ became aware of their HIV 
diagnosis was 12 years [IQR 11, 13]. 
Table 2 presents HIV-related clinical markers for PHIV+ participants, stratified by CDC class C 
diagnosis.  For the 76 (27%) with a CDC C diagnosis, the median age at the first CDC C event was 
2.8 years (interquartile range, IQR 0.5, 6.4), and 11 diagnoses were encephalopathy (median age 
at diagnosis 2.5 years (IQR 0.8,3.5)).  Those with a CDC C were more likely to present to HIV care 
at a younger age and in earlier calendar years, and initiate ART at a younger age. Around three-
quarters in each group had a suppressed viral load <50c/ml at interview, whilst CD4 nadir and CD4 
at interview were similar between the groups at around 200 cells/mm3 and 600 cells/mm3 
respectively. 
In terms of comparability to young people with perinatal HIV in the UK and Ireland CHIPS cohort 
who were not in AALPHI, slightly less PHIV+ in AALPHI were male (p=0.005), and a higher 
proportion were born abroad (p<0.001), but the median age and proportion who were black were 
similar (both p values >0.1, Table 1).  For HIV clinical markers, the median age at first presentation 
was lower in AALPHI (p<0.001), and more PHIV+ in AALPHI presented in earlier calendar years 
(p=0.031, Table 2).  A higher proportion of the national cohort remained ART naïve at most recent 
follow-up (p=0.014), but there was no difference in the age at ART initiation (p=0.90).  A similar 
proportion in AALPHI to the national cohort had suppressed viral load at last follow-up, and 
although nadir CD4 count was lower in AALPHI,  there was no difference in CD4 at last follow-up 
(p=0.038, p=0.13 respectively). 
Figure 1 and Supplementary Table 2 present mean z-scores for each cognitive domain and NPZ-6 
scores, by HIV and CDC C status.  For each domain and for NPZ-6 overall, PHIV+ participants with 
CDC C had the poorest performance, and most mean z-scores for all three groups (and all for 
PHIV+ with CDC C) were below reference means.  For executive function, speed of information 
processing memory, and fine motor skills, PHIV+ with CDC C had poorer mean z-scores than PHIV+ 
without CDC C and HIV- participants, and the latter two groups had similar scores.  Scores for 
attention were similar for all three groups, while for learning, both groups of PHIV+ scored more 
poorly than HIV- participants.  Only for fine motor skills were mean z-scores for PHIV+ without 
CDC C and HIV- groups above the mean score.  However for most domains and groups, mean 
7 
 
scores and 95% confidence intervals were within one standard deviation below the reference 
mean. 
The NPZ-6 reflected the general trend of PHIV+ with CDC C scoring significantly worse than PHIV+ 
without a CDC C and HIV- participants (mean z-score (SD) -0.81 (0.99), -0.45 (0.80), -0.32 (0.76) 
respectively, p<0.001).  Forty-six (61%) PHIV+ young people with CDC C were classified as having 
cognitive impairment, compared to 100 (46%) PHIV+ with no CDC C, and 36 (40%) of HIV- 
participants (p=0.024). 
Table 4 presents univariable and multivariable predictors of improved NPZ-6 scores, for all a priori 
factors as well as those with univariable p<0.15 or multivariable p<0.05.  There was no difference 
in NPZ-6 score between PHIV+ without CDC C and HIV- participants overall, although PHIV+ with a 
CDC C scored more poorly both before and after adjustment for other variables.  Both before and 
after adjustment for other factors, NPZ-6 score improved with each year increase in age 
(multivariable coefficient 0.06, 95% CI 0.02, 0.09), and was lower in black African young people 
(multivariable coefficient -0.46, 95% CI -0.68, -0.24) and those with worse depression scores 
(multivariable coefficient -0.04, 95% CI -0.06, -0.01).  Having been born outside the UK/Ireland, 
parent death, number of adult carers, IDACI deprivation score, never having alcohol or drugs were 
all associated with lower NPZ-6 in univariable analyses but not in multivariable analyses (all 
multivariable p values >0.05).  Black African participants were more likely to have been born 
outside of the UK/Ireland, experienced the death of a parent, had more adult carers and a greater 
deprivation score, and so univariable associations between these factors and NPZ-6 were 
weakened after multivariable adjustment for ethnicity (data not shown).  In a sensitivity analysis 
excluding ethnicity, greater deprivation score was associated with lower NPZ-6 after adjustment 
for other factors (p=0.032), but not death of parents (data not shown). 
Additional sensitivity analyses excluding participants who had experienced encephalopathy found 
a similar trend of PHIV+ with CDC C performing more poorly than the other two groups, and 
allowing for clustering of sibling pairs also did not change the overall model results (data not 
shown).  A separate model for PHIV+ only found similar results to the overall model, and no other 
HIV-related health factors were associated with NPZ-6 scores (data not shown). 
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DISCUSSION 
In our study we found no difference in cognitive scores between PHIV+ without a CDC C diagnosis 
and HIV- participants.  The young people included represent many different countries of origin, 
with around two-thirds having been born outside of the UK/Ireland, predominantly in sub-
Saharan Africa.  They will have experienced varying education in childhood, and different levels of 
familial cultural adjustment to life in England.  Findings have relevance to the many PHIV+ young 
people living in countries across Europe,[33] many of whom similarly started ART after infancy 
and/or are from sub-Saharan Africa.[17, 34, 35] 
In our study domains with the poorest scores were executive function and information processing 
speed, similar to previous findings.[3, 5, 7, 36]  Many young people had domain-specific and 
summary NPZ-6 cognitive scores within one standard deviation below the mean for the normative 
data, which may not have any functional significance.  Further, the differences in individual 
domain and overall scores between HIV- and PHIV+ without a CDC diagnosis were relatively small.  
This finding suggests that contemporary cohorts of HIV positive children who avoid severe disease 
prior to starting ART are at similar risk of cognitive problems as their HIV uninfected peers, and 
that some problems may be subtle. 
Whilst PHIV+ without CDC C diagnoses scored similarly to HIV- participants, both groups scored 
worse than available normative data, similar to a USA study,[3] and 31% and 23% respectively had 
a z-score lower than -2 in at least one domain  This is not unexpected, as young people in our 
study are not representative of the surrounding adolescent population where they live, either 
ethnically or culturally.  Indeed, normative data for CogState comprise largely male Caucasian 
Australian adults;[37] had we not carefully recruited a comparative control population in our 
study we may have concluded that cognitive impairment was more prevalent in all adolescents 
with perinatally acquired HIV.  Conversely, in this cohort of long-term survivors of perinatal HIV, 
PHIV+ participants with CDC C diagnoses had the poorest cognition.  Most of the CDC C events 
were experienced in early life, indicating the importance of early initiation of ART to minimise 
disease severity and long-term sequelae.[3, 13, 38, 39] 
Other independent risk factors for poorer NPZ-6 were younger age, black African ethnicity, and 
worse depression, but not HIV-related factors.  As NPZ-6 is age-adjusted, findings may suggest 
recovery as PHIV+ mature and develop other compensatory skills.  Poorer results for those of 
black African ethnicity are unlikely to be due to linguistic fluency, as many were born in the UK or 
in English-speaking countries.  Additionally many of the CogState tests were non-verbal, but the 
predominance of Caucasian males in the normative dataset may inhibit complete adjustment for 
ethnicity in our study.  These potential problems highlight the importance of recruiting study-
specific control groups as well as careful adjustment for demographic variables;[19, 40] our 
sensitivity analysis showed a separate effect of deprivation score on lower NPZ-6, and socio-
economic status has itself been associated with cognitive function.[41]  Depression has been 
associated with poorer cognition in studies of HIV-infected adults, consistent with the association 
found in our study.[42, 43]  We found that parent death, more adult carers, ever having alcohol 
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and ever taking recreational drugs were associated with NPZ-6 in univariable analyses, but their 
effect was weakened after adjustment for ethnic group.  
Our study has a number of limitations.  Firstly, its cross-sectional nature means that we are unable 
to draw causal inferences about the direction of associations found with NPZ-6.  Secondly, the 
study could not differentiate the effect of HIV versus ART exposure on cognition, or the specific 
effects of individual ART drugs.  Thirdly, although all PHIV+ young people were invited to join 
AALPHI, those with severe cognitive impairment may not have been referred to the study.  
However those included were quite representative of the national adolescent cohort in the 
UK/Ireland, and stratification by CDC C stage controlled for some differences.  Fourthly, among 
HIV- participants, prenatal ART exposure was not measured as two-thirds were born outside the 
UK/Ireland.  Fifth, we did not have the statistical power to investigate multiplicative effects of 
combined variables on cognitive function.  However to our knowledge ours is the first study to 
recruit a substantial number of PHIV+ as well as HIV- affected older adolescents about to embark 
on adult life. 
In conclusion, our study of older adolescents with PHIV and a comparable group of HIV- young 
people affected by HIV found that cognitive scores over a range of domains were similar for PHIV+ 
without a CDC C diagnosis and HIV- participants, and indicated mild rather than severe 
impairment.  Although the drive to halt all new infections in infants and to provide early ART for 
those infected may prevent severe cognitive complications in the future, there are still many 
children globally with HIV who did not start treatment in early life and for whom cognitive issues 
may be relevant.  The day-to-day impact of cognitive problems on educational and employment 
outcomes in adulthood warrants further investigation. 
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Figure 1: Neurocognitive performance by domain, HIV status and CDC class 
 
Notes: Data points are means with 95% confidence intervals.  P values compare the three groups (HIV-, 
PHIV CDC N/A/B), PHIV CDC C) using ANOVA. 
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Table 1: Characteristics of PHIV+ and HIV- participants in AALPHI, and comparison to PHIV+ in UK/Ireland 
 AALPHI UK/Ireland+ 
 HIV- (n=97) PHIV+ (n=296) P value* PHIV+ (n=698) P value** 
 
n (%) or median [IQR] or mean [SD] 
Sociodemographics:      
Sex (male) 31 (32%) 125 (42%) 0.073 363 (52%) 0.005 
Age  
 
   
≤15 years 41 (42%) 116 (39%) 0.768 264 (38%) 0.900 
16-18 years 35 (36%) 119 (40%)  283 (41%)  
≥19 years 21 (22%) 61 (21%)  151 (22%)  
Median 16 [14,18] 16 [15,18] 0.820 16 [14,18] 0.689 
Ethnicity (black) 69 (71%) 251 (85%) 0.003 560 (81%) 0.115 
Born outside UK/Ireland 59 (61%) 228 (77%) 0.002 445 (64%) <0.001 
      
Psychosocial:      
Death of one/both parents  22 (24%) 101 (36%) 0.023 
  
Live with parents 86 (89%) 269 (92%) 0.402   
Occupation      
   School 89 (92%) 273 (92%) 0.734   
   Employment 4 (4%) 8 (3%)    
   Not in education or 
training 
4 (4%) 15 (5%)    
P rent/ carer in work 56 (58%) 210 (71%) 0.043   
Ever excluded from school 23 (24%) 51 (17%) 0.165   
      
Environmental:      
Fostered/adopted 0 (0%) 14 (11%) 0.019   
Number of adult carers 1 [1,2] 1 [1,2] 0.318   
Language at home 
 
 
     
   English only 44 (45%) 154 (52%) 0.391   
   English and another 
equally 
49 (51%) 134 (45%)    
   Language other than 
English 
4 (4%) 7 (2%)    
Mean IDACI deprivation 
score 
0.45 [0.14] 0.39 [0.18] 0.012   
      
Lifestyle:      
Ever smoked 24 (26%) 52 (18%) 0.122   
Ever alcohol 42 (45%) 115 (40%) 0.428   
Ever recreational drugs 25 (28%) 40 (14%) 0.003   
      
Mental health:      
Mean HADS anxiety score 6.1 [4.1] 6.5 [4.0] 0.279   
Mean HADS depression 
score 
3.5 [3.0] 3.9 [3.2] 0.069   
+ UK/Ireland numbers are for PHIV+ aged 13-21 years in the national CHIPS cohort who are not in AALPHI 
* P value comparing HIV- to PHIV+ in AALPHI 
**P value comparing PHIV+ in AALPHI to PHIV+ aged 13-21 years in the national CHIPS cohort. 
The grey shaded area represents variables not measured in CHIPS, hence no comparison was possible. 
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Table 2: HIV clinical markers for PHIV+ with and without a CDC C diagnosis in AALPHI, and comparison to PHIV+ in UK/Ireland 
 PHIV+ in AALPHI PHIV+ in UK/Ireland+ 
 No CDC C (n=210) CDC C (n=76) Total (n=286) PHIV+ (n=698) P value* 
 n (%) or median [IQR] 
Age at first presentation      
Birth 18 (9%) 6 (8%) 24 (8%) 46 (7%) 0.030 
<1 year 27 (13%) 
52 (25%) 
 
25 (33%) 52 (18%) 88 (13%)  
1-4 years 52 (25 ) 25 (33%) 77 (27%) 170 (24%)  
5-9 years 67 (32%) 14 (18%) 81 (28%) 217 (31%)  
≥10 years 46 (22%) 6 (8%) 52 (18%) 176 (25%)  
Median age 5 [1,9] 1.5 [0,5] 4.0 [0.0,8.0] 6 [2,10] 0.001 
Year of first presentation      
Up to 1996 33 (16%) 16 (21%) 49 (17%) 78 (11%) 0.040 
1997-2000 43 (20%) 26 (34%) 69 (24%) 177 (25%)  
2001 onwards 134 (64%) 34 (45%) 168 (59%) 443 (63%)  
ART status at interview      
Naïve 24 (8%) 0 (0%) 24 (8%) 104 (15%) 0.006 
On ART 175 (83%) 72 (95%) 247 (86%) 541 (78%)  
Off ART (previous ART exposure) 11 (5%) 4 (5%) 15 (5%) 53 (8%)  
Age at initiation of ART (on or off ART only) 8.0 [5.1,11.8] 3.8 [1.3,6.2] 6.8 [3.5,10.9] 7.1 [3.0,11.1] 0.775 
Year initiated ART (on or off ART only)      
Up to 1996 0 (0%) 1 (1%) 1 (<1%) 31 (5%) 0.002 
1997-2000 41 (22%) 37 (49%) 78 (30%) 158 (27%)  
2001 onwards 144 (78%) 38 (50%) 182 (70%) 405 (68%)  
Taking efavirenz at interview (on ART only) 61 (29%) 16 (21%) 77 (27%) 183 (34%) 0.042 
Viral load <50c/ml at interview (on ART only) 138 (79%) 49 (68%) 187 (76%) 204 (71%) 0.205 
Median cumulative years VL<400c/ml 5.7 [2.5,8.4] 7.5 [4.4,10.7] 5.9 [3.1,9.2] 4.7 [2.0,7.9] <0.001 
CD4 nadir (cells/mm3) 226 [131,370] 197 [43,325] 220 [120,354] 260 [153,375] 0.001 
CD4 at interview (cells/mm3) 582 [406,769] 641 [422,873] 599 [407,790] 620 [477,810] 0.057 
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+ UK/Ireland numbers are for PHIV+ aged 13-21 years in the national CHIPS cohort who are not in AALPHI 
*P value comparing all PHIV+ in AALPHI to CHIPS aged 13-21 years. 
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Table 4: Univariable and multivariable predictors* of improved NPZ-6 scores 
Variable Univariable predictors of NPZ-6 Multivariable predictors of NPZ-6 
 Coefficient 95% CI p value Coefficient 95% CI p value 
Constant -0.32 -0.48,-0.15  -0.73 -1.36, -0.10  
       
HIV/CDC status (v. HIV-)   <0.001   <0.001 
  PHIV+ no C -0.13 -0.33, 0.07  -0.01 -0.22, 0.20  
  PHIV+ C -0.50 -0.75, -0.24  -0.44 -0.70, -0.19  
       
Sociodemographics:       
Sex, female (v. male) 0.06 -0.11, 0.24 0.472 0.01 -0.16, 0.19 0.867 
       
Age, per year increase 0.05 0.02, 0.08 0.004 0.06 0.02, 0.09 0.002 
       
Ethnicity, black African (v. other) -0.44 -0.66, -0.23 <0.001 -0.46 -0.68, -0.24 <0.001 
       
Born outside of UK/Ireland -0.16 -0.35, 0.03 0.090 -0.10 -0.29, 0.09 0.292 
       
Psychosocial:       
Parent death (v. both parents alive)   0.015    
  One parent died -0.08 -0.28, 0.11  -   
  Both parents died -0.62 -1.04, -0.20  -   
       
Environmental:       
No. adult carers, per 1 carer increase -0.04 -0.09, 0.01 0.138 -   
       
IDACI deprivation score, per unit inc. -0.49 -1.03, 0.06 0.079 -   
       
Lifestyle:       
Ever alcohol 0.33 0.16, 0.50 <0.001 -   
       
Ever recreational drugs 0.39 0.17, 0.62 <0.001 -   
       
Mental health:       
Depression score, per unit worse -0.04 -0.06, -0.01 0.014 -0.04 -0.06, -0.01 0.011 
       
Notes 
*All a priori variables, as well as those with univariable p<0.15 are presented here. 
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Supplementary Table 1: Neurocognitive domains, tools and tests 
Domain Tool Test 
Executive function 
Cogstate Groton Maze 
Color Trails Test Color Trails 2 (normative data for age 18-29 years, with 7-9 years of education) 
Speed of info. 
Processing 
Cogstate Detection task (age adjusted) 
Color Trails Test Color Trails 1 (normative data for age 18-29 years, with 7-9 years of education) 
Attention/working 
memory 
Cogstate Identification Task (age adjusted) 
WAIS-IV Coding (raw no. correct) (normative data not available so omitted from NPZ-6) 
Learning 
Cogstate One card learning (age adjusted) 
Cogstate International shopping list 
Memory 
Cogstate International shopping list delayed 
Cogstate One back task 
Fine motor skills 
Grooved pegboard Pegboard dominant hand (age/sex adjusted) 
Grooved pegboard Pegboard non-dominant hand (age/sex adjusted) 
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Supplementary Table 2: Mean z-scores by neurocognitive domain in PHIV+ with a CDC C diagnosis, PHIV+ with no CDC C diagnosis, and HIV- 
participants 
Domain 
Mean z-score (standard deviation)  
HIV- (n=97) PHIV+ no C (n=210) PHIV+ C (n=76) p 
Executive function -0.68 (0.92) -0.83 (1.61) -1.24 (1.34) 0.031 
Speed of information processing -0.58 (1.23) -0.88 (1.39) -1.24 (1.29) 0.006 
Attention/concentration -0.55 (1.19) -0.53 (1.13) -0.72 (1.18) 0.469 
Learning -0.13 (0.94) -0.42 (0.95) -0.52 (0.92) 0.015 
Memory -0.25 (0.87) -0.42 (0.91) -0.78 (0.90) <0.001 
Fine motor skills 0.35 (1.09) 0.40 (1.41) -0.31 (2.41) 0.003 
NPZ-6 -0.32 (0.76) -0.45 (0.80) -0.81 (0.99) <0.001 
Notes: P values compare the three groups (HIV-, PHIV CDC N/A/B), PHIV CDC C) using ANOVA. 
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